In a study of our group with 561 patients cared for on an MSU, the blood biomarker copeptin (C-terminal proAVP) showed no statistically significant differences in its levels in patients with cerebrovascular disease and other neurological diseases, as well as vascular and non-vascular diseases (35). This evidence concerns the gene AVP and cerebrovascular disorder.